Pernix Therapeutics Holdings is a pharmaceutical company focused on the acquisition, development and commercialization of prescription drugs, primarily for the U.S. market. Co. targets therapeutic areas such as central nervous system, including pain, psychiatry and neurology. Co.'s branded products include: Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor (doxepin), non-narcotic, non-scheduled and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance; and Treximet (sumatriptan/naproxen sodium), a medication indicated for the acute treatment of migraine pain and inflammation. The PTX average annual return 10 years is shown above.
The Average Annual Return on the PTX average annual return 10 years page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether PTX average annual return 10 years or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PTX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Video: Don't Forget Dividends in Average Annual Return!
